Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
-12.11%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$3.97B
AUM Growth
-$900M
(-18%)
Cap. Flow
-$134M
Cap. Flow
% of AUM
-3.37%
Top 10 Holdings %
Top 10 Hldgs %
21.23%
Holding
969
New
42
Increased
273
Reduced
549
Closed
52
Top Buys
| 1 |
McDonald's
MCD
|
$20.9M |
| 2 |
Johnson & Johnson
JNJ
|
$14M |
| 3 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
$12.7M |
| 4 |
Vanguard Intermediate-Term Corporate Bond ETF
VCIT
|
$11M |
| 5 |
MSCI
MSCI
|
$10.7M |
Top Sells
| 1 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
$32.8M |
| 2 |
Home Depot
HD
|
$21.5M |
| 3 |
JPMorgan Chase
JPM
|
$9.67M |
| 4 |
AET
Aetna Inc
AET
|
$9.02M |
| 5 |
Nike
NKE
|
$8.82M |
Sector Composition
| 1 | Technology | 16.16% |
| 2 | Healthcare | 14.34% |
| 3 | Financials | 13.95% |
| 4 | Consumer Discretionary | 11% |
| 5 | Industrials | 9.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CSR
826
Centerspace
CSR
$1.01B
| $117K | ﹤0.01% |
2,298
+470
| +26% | +$23.9K |
|
|
DRNA
827
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $116K | ﹤0.01% |
10,673
+163
| +2% | +$1.77K |
|
828
Atara Biotherapeutics
ATRA
$90.7M
| $115K | ﹤0.01% |
162
+39
| +32% | +$27.7K |
|
829
AngioDynamics
ANGO
$436M
| $113K | ﹤0.01% |
+5,800
| New | +$113K |
|
830
Editas Medicine
EDIT
$248M
| $113K | ﹤0.01% |
5,160
+1,314
| +34% | +$28.8K |
|
831
NVE Corp
NVEC
$323M
| $113K | ﹤0.01% |
+1,302
| New | +$113K |
|
832
CRISPR Therapeutics
CRSP
$4.99B
| $112K | ﹤0.01% |
3,987
+1,765
| +79% | +$49.6K |
|
833
Ultra Clean Holdings
UCTT
$1.11B
| $112K | ﹤0.01% |
13,436
+8,414
| +168% | +$70.1K |
|
|
BLUE
834
DELISTED
bluebird bio
BLUE
| $110K | ﹤0.01% |
85
+23
| +37% | +$29.8K |
|
835
Ionis Pharmaceuticals
IONS
$9.76B
| $110K | ﹤0.01% |
2,080
-272
| -12% | -$14.4K |
|
836
Intellia Therapeutics
NTLA
$1.29B
| $110K | ﹤0.01% |
8,381
+2,892
| +53% | +$38K |
|
|
CLLS
837
Cellectis
CLLS
$269M
| $109K | ﹤0.01% |
6,545
+1,787
| +38% | +$29.8K |
|
|
AEGN
838
DELISTED
Aegion Corp
AEGN
| $109K | ﹤0.01% |
6,532
+2,875
| +79% | +$48K |
|
839
Novartis
NVS
$251B
| $108K | ﹤0.01% |
1,417
-86
| -6% | -$6.56K |
|
840
Forum Energy Technologies
FET
$309M
| $107K | ﹤0.01% |
+1,191
| New | +$107K |
|
841
CONMED
CNMD
$1.7B
| $106K | ﹤0.01% |
1,742
+454
| +35% | +$27.6K |
|
842
Sanofi
SNY
$113B
| $106K | ﹤0.01% |
2,486
-253
| -9% | -$10.8K |
|
843
Grifois
GRFS
$6.89B
| $105K | ﹤0.01% |
5,770
+1,799
| +45% | +$32.7K |
|
|
LDL
844
DELISTED
Lydall, Inc.
LDL
| $105K | ﹤0.01% |
+5,244
| New | +$105K |
|
845
Camtek
CAMT
$3.6B
| $104K | ﹤0.01% |
+15,413
| New | +$104K |
|
846
Stellantis
STLA
$26.2B
| $104K | ﹤0.01% |
7,358
+3,367
| +84% | +$47.6K |
|
|
HT
847
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $104K | ﹤0.01% |
6,249
| – | – |
|
|
APTS
848
DELISTED
Preferred Apartment Communities, Inc.
APTS
| $102K | ﹤0.01% |
7,157
| – | – |
|
849
Alaunos Therapeutics
TCRT
$4.27M
| $101K | ﹤0.01% |
314
+114
| +57% | +$36.7K |
|
850
Voyager Therapeutics
VYGR
$235M
| $101K | ﹤0.01% |
11,380
+4,559
| +67% | +$40.5K |
|